Additive Clinical Effect of Indomethacin Suppositories During Salicylate Therapy in Rheumatoid Patients

References

• Borgå O., Odar-Cederlöf I., Ringberger V.-A., Norlin A. Protein binding of salicylate in uremic and normal plasma. Clin Pharmacol Ther 1976; 4: 464
   Google Scholar
• Brodie B. B., Udenfriend S., Coburn A. F. The determination of salicylic acid in plasma. J Pharmacol Ther 1944; 80: 114
   Google Scholar
• Brooks P. M., Walker J. J., Bell M. A., Buchanan W. W., Rhymer A. R. Indomethacin-aspirin interaction: a clinical reappraisal. Brit Med J 1975; iii: 69
   Google Scholar
• Donnelly P., Lloyd K., Campbell H. Indometha-cin in rheumatoid arthritis: An evaluation of its antiinflammatory and side effects. Brit Med J 1967; i: 69
   Google Scholar
• Ehrnebo M., Agurell S., Jailing B., Boréus L.-O. Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Europ J Clin Pharmacol J 1971; 189
   Google Scholar
• Ekstrand R., Alván G., Borgå O. Concentration dependent plasma protein binding of salicylate in rheumatoid patients. Clin Pharmacokin 1979; 4: 137
   PubMed Web of Science ®Google Scholar
• Ekstrand R., Alván G., Orme M., Lewander R., Palmér L., Sarby B. Double-blind dose-response study of indomethacin in rheumatoid arthritis. Europ J Clin Pharmacol. 1980; 17: 437
   PubMed Web of Science ®Google Scholar
• Ferreira S. H., Vane J. R. New aspects of the mode of action of nonsteroid anti-inflammatory drugs. Ann Rev Pharm 1974; 14: 57
   Google Scholar
• Flower R. J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974; 26: 33
   PubMed Web of Science ®Google Scholar
• Furst D. E., Tozer T. N., Melmon K. L. Salicylate clearance, the resultant of protein binding and metabolism. Clin Pharmacol Ther 1979; 3: 380
   Google Scholar
• Grennan D. M., Ferry D. G., Ashworth M. E., Kenny R. E., Mackinnon M. The aspirin-ibupro-fen interaction in rheumatoid arthritis. Br J Clin Pharmacol 1979; 8: 497
   PubMed Web of Science ®Google Scholar
• Hamberg M. Inhibition of prostaglandin synthesis in man. Biochem Biophys Res Com 1972; 3: 720
   Google Scholar
• Joyce C. R. B., Zutshi D. W., Hrubes V., Mason R. M. Comparison of fixed interval and visual analogue scales for rating chronic pain. Europ J Clin Pharmacol 1975; 18: 415
   Google Scholar
• Levy G. Pharmacokinetics of salicylate elimination in man. J Pharm Sci 1965; 54: 959
   PubMed Web of Science ®Google Scholar
• Levy G., Tsuchiya T., Amsel P. Limited capacity for salicyl phenolic glucuronide formation and its effect on kinetics of salicylate elimination in man. Clin Pharmacol Ther 1972; 13: 258
   PubMed Web of Science ®Google Scholar
• Miller R. L., Melmon K. L. Inflammatory disorders. Clinical Pharmacology-Basic Principles in Therapeutics, K. L. Melmon, H. F. Morelli. Macmillan, New York 1972; 407
   Google Scholar
• Oliw E., Lundén I., Änggård E. In vivo inhibition of prostaglandin synthesis in rabbit kidney by nonsteroidal anti-inflammatory drugs. Acta Pharmacol Toxicol 1978; 42: 179
   PubMedGoogle Scholar
• Palmér L., Bertilsson L., Alván G., Orme M., Sjöqvist F., Holmstedt B. Indomethacin: Quan-tiative determination in plasma by mass fragmento-graphy including pilot pharmacokinetics in man. Prostaglandin Synthetase Inhibitors, H. J. Robinson, J. R. Vane. Raven Press, New York 1974; 91
   Google Scholar
• Pinals R. S., Frank S. Relative efficacy of indomethacin and acetylsalicylic acid in rheumatoid arthritis. New England J Med 1967; 276: 512
   PubMed Web of Science ®Google Scholar
• Pitkeathly D. A., Banerhee N. R., Harris R., Sharp J. Indomethacin in patients treatment of rheumatoid arthritis. Ann Rheum Dis 1966; 25: 334
   PubMed Web of Science ®Google Scholar
• Rane A., Oelz O., Frolich J. C., Seyberth H., Sweetman B., Watson J. T., Wilkinson G. R., Oates J. A. Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther 1978; 6: 658
   Google Scholar
• Ritchie D. M., Boyle J. A., McLnnes J. M., Jasani M. K., Dalakos T. G., Grieveson P., Buchanan W. W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Quart J Med 1968; 37: 393
   PubMedGoogle Scholar
• Ropes M. W., Bennet G. A., Cobb S., Jacox R., Jessar R. A. Revision of diagnostic criteria for rheumatoid arthritis. Ann Rheum Dis 1959; 18: 49
   PubMed Web of Science ®Google Scholar
• Roth G. J., Majerus P. W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624
   PubMed Web of Science ®Google Scholar
• Smith J. B., Willis A. L. Aspirin selectively inhibits prostaglandin production in human platelets. Nature (New Biol) 1971; 231: 235
   PubMedGoogle Scholar
• Tomson G., Lunell N. O., Oliw E., Rane A. Naproxen kinetics and its relation to the effects on platelet prostaglandin release in men and dysmenor-rhoeic women. Clin Pharmacol Ther, (in press)
   Google Scholar
• Trang L. E., Granström E., Lövgren O. Levels of prostaglandins F2α and E2 and thromboxane B2 in joint fluid in rheumatoid arthritis. Scand J Rheumatol 1977; 6: 151
   PubMed Web of Science ®Google Scholar
• Weiss H. J., Aledort L. M., Kochwa S. The effects of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968; 47: 2169
   PubMed Web of Science ®Google Scholar
• Winter G. A., Risley E. A., Nuss G. W. Anti-inflammatory and antipyretic activities of indomethacin, l-(p-chloro-benzoyl)-5-methoxy-2-methylindole-3-acetic acid. J Pharmacol Exp Ther 1963; 141: 369
   PubMed Web of Science ®Google Scholar
• Zimmerman H. J. Iatrogenic hepatic injury. Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. Appleton-Cen-tury-Crofts, New York 1978; 428
   Google Scholar